Modification of soluble immunological parameters during treatment with interleukin-2

I. Abbate, M. Correale, M. D. Musci, M. Guida, C. D. Dragone, M. De Santis, M. De Lena

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

In the present study we tested numerous soluble immunological parameters (soluble Interleukin 2 receptor, Beta 2 microglobulin, Neopterin, soluble CD8 antigen, gamma Interferon and alpha Tumor Necrosis Factor) in sera obtained from 18 advanced cancer patients during subcutaneous treatment with recombinant Interleukin 2. The treatment cycles consisted of a dose of 9 x 106 IU/m2 twice daily for 2 days followed by 1.8 x 106 IU/m2 twice daily for 5 days/week during 6 weeks. Even before therapy, neoplastic patients had higher levels of soluble Interleukin 2 receptor than a group of healthy subjects. Moreover, basal soluble CD8 antigen levels showed significant differences (p <0.01) in patients with different clinical responses (responders and non-responders). During treatment we observed a fast increase (in the first or second week) of all parameters considered; soluble Interleukin 2 receptor and soluble CD8 antigen were the markers that were best related to the course of immunotherapy. In conclusion, monitoring recombinant Interleukin 2 immunotherapy with immunological parameters in serum seems to be of interest. However, more data are necessary to confirm the real value of the single markers.

Original languageEnglish
Pages (from-to)227-232
Number of pages6
JournalInternational Journal of Biological Markers
Volume8
Issue number4
Publication statusPublished - 1993

Fingerprint

CD8 Antigens
Interleukin-2
Interleukin-2 Receptors
Interleukin-2 Receptor beta Subunit
Immunotherapy
Neopterin
beta 2-Microglobulin
Interferon-alpha
Interferon-gamma
Therapeutics
Tumor Necrosis Factor-alpha
Serum
Healthy Volunteers
Monitoring
Neoplasms

ASJC Scopus subject areas

  • Biochemistry
  • Immunology

Cite this

Abbate, I., Correale, M., Musci, M. D., Guida, M., Dragone, C. D., De Santis, M., & De Lena, M. (1993). Modification of soluble immunological parameters during treatment with interleukin-2. International Journal of Biological Markers, 8(4), 227-232.

Modification of soluble immunological parameters during treatment with interleukin-2. / Abbate, I.; Correale, M.; Musci, M. D.; Guida, M.; Dragone, C. D.; De Santis, M.; De Lena, M.

In: International Journal of Biological Markers, Vol. 8, No. 4, 1993, p. 227-232.

Research output: Contribution to journalArticle

Abbate, I, Correale, M, Musci, MD, Guida, M, Dragone, CD, De Santis, M & De Lena, M 1993, 'Modification of soluble immunological parameters during treatment with interleukin-2', International Journal of Biological Markers, vol. 8, no. 4, pp. 227-232.
Abbate, I. ; Correale, M. ; Musci, M. D. ; Guida, M. ; Dragone, C. D. ; De Santis, M. ; De Lena, M. / Modification of soluble immunological parameters during treatment with interleukin-2. In: International Journal of Biological Markers. 1993 ; Vol. 8, No. 4. pp. 227-232.
@article{9e3edb67ed3c4c30ad89a8c773a03702,
title = "Modification of soluble immunological parameters during treatment with interleukin-2",
abstract = "In the present study we tested numerous soluble immunological parameters (soluble Interleukin 2 receptor, Beta 2 microglobulin, Neopterin, soluble CD8 antigen, gamma Interferon and alpha Tumor Necrosis Factor) in sera obtained from 18 advanced cancer patients during subcutaneous treatment with recombinant Interleukin 2. The treatment cycles consisted of a dose of 9 x 106 IU/m2 twice daily for 2 days followed by 1.8 x 106 IU/m2 twice daily for 5 days/week during 6 weeks. Even before therapy, neoplastic patients had higher levels of soluble Interleukin 2 receptor than a group of healthy subjects. Moreover, basal soluble CD8 antigen levels showed significant differences (p <0.01) in patients with different clinical responses (responders and non-responders). During treatment we observed a fast increase (in the first or second week) of all parameters considered; soluble Interleukin 2 receptor and soluble CD8 antigen were the markers that were best related to the course of immunotherapy. In conclusion, monitoring recombinant Interleukin 2 immunotherapy with immunological parameters in serum seems to be of interest. However, more data are necessary to confirm the real value of the single markers.",
author = "I. Abbate and M. Correale and Musci, {M. D.} and M. Guida and Dragone, {C. D.} and {De Santis}, M. and {De Lena}, M.",
year = "1993",
language = "English",
volume = "8",
pages = "227--232",
journal = "International Journal of Biological Markers",
issn = "0393-6155",
publisher = "Wichtig Publishing Srl",
number = "4",

}

TY - JOUR

T1 - Modification of soluble immunological parameters during treatment with interleukin-2

AU - Abbate, I.

AU - Correale, M.

AU - Musci, M. D.

AU - Guida, M.

AU - Dragone, C. D.

AU - De Santis, M.

AU - De Lena, M.

PY - 1993

Y1 - 1993

N2 - In the present study we tested numerous soluble immunological parameters (soluble Interleukin 2 receptor, Beta 2 microglobulin, Neopterin, soluble CD8 antigen, gamma Interferon and alpha Tumor Necrosis Factor) in sera obtained from 18 advanced cancer patients during subcutaneous treatment with recombinant Interleukin 2. The treatment cycles consisted of a dose of 9 x 106 IU/m2 twice daily for 2 days followed by 1.8 x 106 IU/m2 twice daily for 5 days/week during 6 weeks. Even before therapy, neoplastic patients had higher levels of soluble Interleukin 2 receptor than a group of healthy subjects. Moreover, basal soluble CD8 antigen levels showed significant differences (p <0.01) in patients with different clinical responses (responders and non-responders). During treatment we observed a fast increase (in the first or second week) of all parameters considered; soluble Interleukin 2 receptor and soluble CD8 antigen were the markers that were best related to the course of immunotherapy. In conclusion, monitoring recombinant Interleukin 2 immunotherapy with immunological parameters in serum seems to be of interest. However, more data are necessary to confirm the real value of the single markers.

AB - In the present study we tested numerous soluble immunological parameters (soluble Interleukin 2 receptor, Beta 2 microglobulin, Neopterin, soluble CD8 antigen, gamma Interferon and alpha Tumor Necrosis Factor) in sera obtained from 18 advanced cancer patients during subcutaneous treatment with recombinant Interleukin 2. The treatment cycles consisted of a dose of 9 x 106 IU/m2 twice daily for 2 days followed by 1.8 x 106 IU/m2 twice daily for 5 days/week during 6 weeks. Even before therapy, neoplastic patients had higher levels of soluble Interleukin 2 receptor than a group of healthy subjects. Moreover, basal soluble CD8 antigen levels showed significant differences (p <0.01) in patients with different clinical responses (responders and non-responders). During treatment we observed a fast increase (in the first or second week) of all parameters considered; soluble Interleukin 2 receptor and soluble CD8 antigen were the markers that were best related to the course of immunotherapy. In conclusion, monitoring recombinant Interleukin 2 immunotherapy with immunological parameters in serum seems to be of interest. However, more data are necessary to confirm the real value of the single markers.

UR - http://www.scopus.com/inward/record.url?scp=0027772682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027772682&partnerID=8YFLogxK

M3 - Article

VL - 8

SP - 227

EP - 232

JO - International Journal of Biological Markers

JF - International Journal of Biological Markers

SN - 0393-6155

IS - 4

ER -